

BLMK AREA PRESCRIBING COMMITTEE (APC) ANNUAL REPORT April 2022 to March 2023



“To promote rational, evidence-based, high quality, cost-effective medicines optimisation across Bedfordshire, Luton and Milton Keynes in order to ensure equity of access to medicines for all residents.”

The following organisations contribute to and participate in the BLMK Area Prescribing Committee – Bedfordshire, Luton and Milton Keynes Integrated Care Board; Bedfordshire Hospitals NHS Foundation Trust; Cambridgeshire Community Services NHS Trust; Central and North West London NHS Foundation Trust; East London NHS Foundation Trust; Milton Keynes University Hospital NHS Foundation Trust

© NHS BLMK ICB April 2023

BLMK AREA PRESCRIBING COMMITTEE (APC) ANNUAL REPORT

April 2022 to March 2023

Introduction

This is the second Annual Report of the BLMK APC, and the contents reflect the output from the committee meetings on 4th May 2022, 29th June 2022, 28th September 2022, 7th December 2022 and 1st March 2023.

At this stage in the report, it is important that we acknowledge the work done by the commitment of committee and subgroup members to making the BLMK APC work effectively, to thank the last chair Alison Borrett for her excellent contribution and leading of committee meetings between April to September 2022, and the recently appointed chair Dr Muhammed Nisar from December 2022 onwards.

The BLMK APC is a strategic local decision-making group with responsibility to promote rational, evidence-based, high quality, cost-effective medicines optimisation across Bedfordshire, Luton and Milton Keynes in order to ensure equity of access to medicines for all residents.

The APC makes decisions in ways that are clear, consistent and defensible and takes account of regional and national recommendations using an explicit ethical framework and decision-making criteria that clinicians are aware of when submitting applications for clinical support and for funding.

There is a systematic approach to whole therapeutic areas, not looking solely at single medicines in isolation from the care pathway; there will be consideration of other health-system costs to support and facilitate service redesign.

The APC includes Medicines Safety and Antimicrobial Stewardship as standing agenda items.

With effect from April 2022 to June 2022 the APC performed this work on behalf of the BLMK Clinical Commissioning Group (CCG) and its partnership organisations. The BLMK Integrated Care Board (ICB) was legally established on 1 July 2022, replacing the CCG and taking on the NHS planning functions previously held by the CCG, therefore from July 2022 onwards the APC performed this work on behalf of the BLMK Integrated Care Board and its partnership organisations.

The role of the APC includes discussion on BLMK wide implementation of national guidance on the use of medicines, such as NICE Technology Appraisals/Guidelines where medicines are included, assessment of the clinical and cost-effectiveness of medicines and medicines excluded from the National Tariff, discussion and agreement of local therapeutic guidelines where there is a large medicines component and assisting in the resolution of



problems relating to prescribing at the primary and secondary care interface. The focus of the Committee has changed in recent years. There has been a shift away from evaluation of new medicines to production of therapeutic guidelines/pathways to assist in safe, effective and cost-effective prescribing. This reflects the changing role of Area Prescribing Committees which now focus more on production of medicine related guidelines.

Please [click here](#) to access the current Terms of Reference of BLMK APC. Output from the BLMK APC can be found in Appendix 1.

APC Subgroups

Three subgroups to the APC have been created. All are advisory and make recommendations to the APC for ratification:

1. **BLMK Formulary Subgroup:** There are currently two joint Formularies - Milton Keynes Joint Formulary and Bedfordshire and Luton Joint Formulary. The BLMK Formulary Subgroup focusses on the evaluation of new medicines and additional preparations of existing medicines with potential impact in primary and secondary care (prescribing or commissioning) for addition to both Joint Formularies. It also reviews sections of the Formularies and prepares shared care guidelines. Acute Trust Drugs and Therapeutics Committees focus on reviewing hospital only drugs. Medicines which are the subject of a positive NICE Technology Appraisal Guidance are automatically added to both Joint Formularies. Please [click here](#) to access the current Terms of Reference of the Formulary Subgroup. While formal merger of the two Joint Formularies is not anticipated in the short term, in the longer term alignment of the Formularies is anticipated as a result of the work of the BLMK Formulary Subgroup.
2. The **BLMK Medicines Safety Group (MSG)** provides information on medicines safety drug updates (DSU) and patient safety alerts to the APC. The MSG is a forum to inform and improve medication safety across the BLMK health economy, sharing of information about and learning from medication safety issues occurring in both primary and secondary care. It also makes medicines safety recommendations which span the interface between primary and secondary care. Please [click here](#) to access the current Terms of Reference of the BLMK Medicines Safety.
3. **Wound Management Formulary Steering Group.** The purpose of the Wound Management Formulary Steering Group is: To provide strategic oversight in all aspects of Wound Management products across the local health economy in Bedfordshire, Luton and Milton Keynes (BLMK). To develop, implement, and monitor the application of wound management documentation, policies, guidance and practice. This



group has been in existence for many years serving Bedfordshire and Luton and has been extended to include representation from Milton Keynes. Please [click here](#) to access the current Terms of Reference of the Wound Management Formulary Steering Group. Work is ongoing to move towards alignment of the wound care formularies across BLMK.

The APC and its subgroups work to their terms of reference, and follow an Ethical and Commissioning Principles framework, incorporating an Equality and Diversity Impact Assessment where applicable (see Appendix 2) when producing recommendations on medicines/guidelines. APC and Subgroup members are asked to complete the current declarations of conflict of interest and do not take part in decision-making where a conflict of interest arises.

Participating Organisations:

The APC serves the following participating NHS organisations:

- Bedfordshire Hospitals NHS Foundation Trust (Bedford site and Luton & Dunstable site)
- Milton Keynes Hospital University Hospital NHS Foundation Trust
- East London Foundation NHS Trust (ELFT) (Provides Mental Health Services to Bedfordshire and Luton and Community Health Services to Bedfordshire).
- Cambridgeshire Community Services NHS Trust (Provides Community Health Services to Luton).
- Central and North West London NHS Foundation Trust (CNWL) (Provides Community and Mental Health Services to Milton Keynes).
- BLMK Integrated Care Board (formerly BLMK Clinical Commissioning Group).

Representation on the APC comes from the participating organisations and is included in the APC Terms of Reference. The Committee chair is a BLMK ICS clinician.

Meeting Attendance Figures

BLMK APC meetings are usually held bi-monthly and the Committee first met in September 2021. There has been a total of five business APC committee meetings held from April 2022 to March 2023. Meetings were held virtually by Microsoft Teams and at dates and times that members have said they would be available. Dates and times of meetings are set at least 6 months in advance of the meeting. The table below illustrates APC member and participating NHS organisations' APC attendance from April 2022 to March 2023 for the five business meetings. (Some members deputise for each other



and % attendance reflects this fact). People who attend in an 'in attendance' capacity are not included in the table.



Job Title	Organisation representing	2022/23 % attendance
Chair	Working on behalf of the Committee	100%
Place Based Lead GP– Milton Keynes or Deputy	BLMK CCG/ICB	100%
Place Based Lead GP – Luton	BLMK CCG/ICB	100%
Place Based Lead GP – Central Bedfordshire	Place Based Lead GP	100%
Place Based Lead GP – Bedford	BLMK CCG/CIB	100%
Pharmacist Representative	Bedfordshire Hospitals NHS Foundation Trust	60%
Pharmacist Representative - Deputy	Bedfordshire Hospitals NHS Foundation Trust	0%
Pharmacist Representative	Milton Keynes University Hospital NHS Foundation Trust	80%
Pharmacist Representative - Deputy	Milton Keynes University Hospital NHS Foundation Trust	40%
Consultant in Public Health	Working on behalf of the Committee	100%
Medical Representative	Bedfordshire Hospitals NHS Foundation Trust	80%
Medical Representative – Deputy	Bedfordshire Hospitals NHS Foundation Trust	60%
Medical Representation	Milton Keynes University Hospital NHS Foundation Trust	40%
Medical Representative – Deputy	Milton Keynes University Hospital NHS Foundation Trust	80%
APC Professional Secretary	Working on behalf of the Committee	100%
Pharmacist Representative	Assisting the Professional Secretary working on behalf of the Committee	100%
Lay Representative	Working on behalf of the Committee	60%
Associate Director and Head of Medicines Optimisation	BLMK CCG/ICB	100%
Place Based Lead Pharmacist – Central Bedfordshire	BLMK CCG/ICB	100%
Place Based Lead Pharmacist – Bedford	BLMK CCG/ICB	100%
Place Based Lead Pharmacist – Luton	BLMK CCG/ICB	100%
Integrated Care Board (ICB) Chief Pharmacist	BLMK CCG/ICB	0%
Chair of Medicines Safety Group	Secondary Care	100%
Chair of Wound Care Group	BLMK CCG/ICB	100%
Chair of Formulary Subgroup	BLMK CCG/ICB	100%
Formulary Lead Pharmacist	BLMK CCG/ICB	100%
Pharmacist Representative	CNWL (Community and Mental Health Services Milton Keynes)	100%
Pharmacist Representative	ELFT (Community Services (Beds)/Mental Health Services (Beds and Luton)	80%
Pharmacist Representative	CCS (Beds & Luton Community Services Provider)	100%



In addition to those outlined above, the Committee also welcomed the attendance and contribution of other colleagues from participating organisations, including observers who attended as part of their non-medical prescribing course.

Committee's Activities and Achievements

• Communication and consultation

Key stakeholders are identified and consulted when medicines/pathways within specialist areas are discussed. As many views as possible are sought and considered during the APC meeting. Specialists/staff with specialist input are invited to attend APC meetings to contribute to the meeting or make presentations. A total of 26 presentations were made over the five business meetings held from May 2022 to March 2023. In addition, where complex guidelines are discussed, clinicians are invited to participate in subgroup meetings prior to full discussion at APC.

A consensus recommendation is reached by APC members, and these are presented in the form of APC recommendations and more detailed APC Guidelines which are communicated to key stakeholders either individually (via email) or through newsletters.

The APC and its Subgroups have produced a variety of guidance on the appropriate and cost-effective use of medicines during the 2022/23 financial year and these are outlined below.

• Guidelines, Pathways and Bulletins

The following Guidelines, Pathways and Bulletins were produced or updated and ratified during the 2022/23 Financial Year:

- Ulcerative Colitis Pathway update
- Osteoporosis guideline update
- Potassium binders treatment pathway
- Buccal midazolam prescribing guidance
- Guidance on the recording of Hospital Only medicines (Recording a Medication without Prescribing on SystemOne)
- COPD Guideline Update
- BLMK Infant Formulae Prescribing Guidelines
- Oral Nutritional Supplement Prescribing Guidelines
- Hyperhidrosis Policy
- Ophthalmology Intravitreal Injection pathway update
- BLMK ICB Hypertension Adult Treatment Guidelines
- Psoriatic arthritis pathway update
- GLP-1 Agonist Prescribing Guideline
- Crohn's Disease Biologic Pathway Update



- Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis Pathway Update
- Vitamins and minerals prescribing guidance
- Blood glucose monitoring
- Guidance on the Management of Type 2 Diabetes in Adults with CVD and HF with SGLT2 inhibitors
- SGLT2 inhibitors for chronic kidney disease
- Place in therapy of Drugs for the Treatment of Type 2 Diabetes
- Interim commissioning statement – high cost drugs for young people under the care of adult services
- Testosterone for low sexual desire in women factsheet update

Copies of the Guidelines, Pathways and Bulletins are available on the [BLMK Medicines Optimisation website](#) with Formulary specific information available by accessing the two joint formularies:

<http://www.bedsformulary.nhs.uk/>

<https://formularymk.nhs.uk/>

- **Shared care guidelines/Information for GPs**

During 2022/2023 the following shared care guidelines/information for GPs were produced/ updated and ratified:

- Hydroxychloroquine fact sheet update.
- Denosumab (Prolia®) for the treatment of Osteoporosis in Post-Menopausal Women and Adult Males (≥ 50 years) at increased risk of fractures.
- ADHD Shared Care Guideline for Adults (Applicable for Luton and Bedfordshire Areas only).
- ADHD/Hyperkinetic Disorder for Children & Young People (6-17 years) (applies to Bedfordshire and Luton only).

These are available on the [BLMK Medicines Optimisation Shared Care Guidelines website](#) along with previous information.

- **Miscellaneous Documents**

The following miscellaneous documents were approved or noted (for information) by the APC Committee during April 2022 to March 2023:

- BLMK Shared Care Guideline Template update
- Treatments for the management of Covid-19
- BLMK APC Terms of Reference
- Risankizumab Early Access to Medicines Scheme
- Cannabis-based products for medicinal use: Patient Registry
- Group A Streptococcus in Children



- Sodium Valproate in women of childbearing potential
- Minutes of meetings from the contributing organisations to the APC

This information can be found on the [BLMK Medicines Optimisation website](#) and via the Joint Formularies (Formulary specific information) - <http://www.bedsformulary.nhs.uk/> <https://formularymk.nhs.uk/>

- **NICE Guidance**

NICE Technology Appraisal Guidance (NICE TAs) and guidelines were noted by the BLMK APC from April 2022 to March 2023. NICE TAs which are the commissioning responsibility of CCGs/ICBs are noted for implementation. NICE Guidelines are noted for information and action where appropriate and NICE TAs where the commissioning responsibility rests with NHS England (NHSE) are noted for information only. As a result of the issue of NICE Guidance, updates to existing APC guidance and BLMK Formulary are undertaken.

See appendix 3 for information on CCG/ICB Commissioned NICE Technology Appraisal Guidance considered by the APC between April 2022 and March 2023.

[Click here](#) to access all NICE Guidance issued from 17th February 2022 to 14th February 2023.

The APC also received reports from its Subgroups and ratified recommendations made at these groups:

- **BLMK Formulary Group**

The Formulary additions and deletions made between April 2022 and March 2023 can be accessed here: [BLMK ICB All Newsletters](#)
The BLMK Formularies can be accessed by clicking on the following links:
<http://www.bedsformulary.nhs.uk/>
<https://formularymk.nhs.uk/>

- **BLMK Medicines Safety Group (MSG)**

The BLMK Medicines Safety group brought the Drug Safety Updates and national Patient Safety Alerts to the APC for information and action. This information can be accessed from April 2022 to March 2023 APC Newsletters:- [All Newsletters – BLMKICB Medicines Management](#)

- **BLMK Wound Management Formulary Steering Group.**

The APC ratifies the formulary recommendations of the BLMK Wound Care Formulary Steering Group which has representation from relevant clinicians across Bedfordshire, Luton and Milton Keynes.



Currently there are two Formularies in operation. The Bedfordshire and Luton Wound Care Formulary can be accessed by clicking on the following link:

[Formulary – BLMKICB Medicines Management](#)

The Milton Keynes Wound Care Formulary for Practice Nurses and Nursing Homes is made available through a system called NWOS: [NWOS Surgical](#)
<https://www.nwosurgical.co.uk/>

Details of additions and deletions made to the Wound Care Formulary between April 2022 and March 2023 can be accessed here: [BLMK ICB All Newsletters](#)

- **Antimicrobial Resistance Update**

Updates are provided to the Committee by the BLMK ICB Lead Antimicrobial Pharmacist, and the information provided can be accessed from April 2022 to March 2023 here: [All Newsletters – BLMKICB Medicines Management](#)

- **East of England Priorities Advisory Committee (EoE PAC)**

Bulletins produced by the APC have been submitted to the EoE PAC to help inform production of East of England wide policies on medicines where it is appropriate to have these. Outputs from EoE PAC are considered and ratified by the APC as appropriate.

The APC ratified the following EoE PAC recommendations and bulletins between April 2022 and March 2023:

- IQoro neuromuscular training device
- Insulin degludec (Tresiba) and insulin glargine (Toujeo) documents (with local amendments)
- Botulinum Toxin Type A – Policy Review (with local amendments)

- **Regional Medicines Optimisation Committees (RMOCs)**

The output from RMOCs is included as a standing agenda item on the APC and are actioned as appropriate.

- **APC Newsletter**

An APC Newsletter is produced following each business meeting of the Committee providing a brief summary of APC recommendations and is widely circulated within the Bedfordshire, Luton and Milton Keynes health economy (Primary care clinicians, Community Pharmacists, and Secondary Care). Five Newsletters have been produced between May 2022 and March 2023 and can be accessed from:

<https://medicines.bedfordshirelutonandmiltonkeynes.icb.nhs.uk/all-newsletters/>

- **Future Work Programme**

The work plan of the APC includes updating, aligning and/or developing new pathways/guidelines including the following:



- Ulcerative Colitis Pathway Update
- Crohn's Disease Pathway Update
- Vitamin D Pathway Update
- Liraglutide for children with type 2 diabetes – prescribing guidance
- Somatostatin analogues guidance update
- Medical devices recommendations
- Continence Appliance Prescribing Guidelines

Summary

The BLMK Area Prescribing Committee has, during the 2022/23 financial year, continued to build on the legacy of its predecessor committees to ensure the provision of recommendations on the safe, clinical and cost-effective use of medicines to the BLMK ICB and provider Trusts to improve patient outcomes of the Bedfordshire, Luton and Milton Keynes population. The meetings have been well attended with good representation from primary care, secondary care and lay members.

Finally, we hope you find this annual report helpful. Any comments on this document are welcomed by the APC Secretary.

APC Secretary contact details:

E-mail: anne.graeff@nhs.net

Arndale House

Luton



**OUTPUT FROM THE BLMK AREA PRESCRIBING COMMITTEES HELD
BETWEEN APRIL 2022 AND MARCH 2023**

The approved APC meeting notes can be accessed via the following links:

[4th May 2022](#)

[29th June 2022](#)

[28th September 2022](#)

[7th December 2022](#)


[1st March 2023](#)

The APC Newsletters (summarising decisions made at the meetings) and Formulary Newsletters (to include agreed updates to the Bedfordshire and Luton Joint Formulary and Milton Keynes Joint Formulary) can be accessed via the following link:

[Newsletters](#)



Bedfordshire, Luton and Milton Keynes (BLMK) Area Prescribing Committee (APC)
Assessment against Ethical and Commissioning Principles

Treatment assessed (Month and Year):
APC Recommendation TBC post meeting
1) Clinical Effectiveness <i>e.g. according to national guidelines...</i>
2) Cost Effectiveness <i>e.g. most appropriate and cost- effective products have been recommended</i>
3) Needs of the community <i>e.g. prevalence and incidence of disease being treated?</i>
<p>4) Equity & Equality Impact Assessment (see also embedded additional information including factsheet below to aid completion of this section)</p> <p>Consider whether this decision of the APC will have an impact for patients or staff in regard to Equality, Inclusion and Human Rights legislation. Such impacts (negative) could include:</p> <ul style="list-style-type: none"> • Restriction of a drug which could benefit those with certain conditions^{1,2} <p>Where the implementation of the decision of the BLMK APC may impact on one or more equality group differently to others, a full equality impact assessment may need to be completed as advised by the BLMK Equality and Diversity Lead.</p> <div style="border: 1px solid black; padding: 5px; margin: 10px auto; width: fit-content;"> <p>Protected Characteristics (under the Equality Act 2010): Age; Disability; Gender reassignment; Marriage & Civil Partnership (in employment only); Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual orientation; carers; other identified groups.</p> </div> <div style="text-align: center; margin: 10px auto;">  Equality Impact Assessment Factsheet </div> <p>¹ NB Equality and Diversity is only one part of an assessment of the new drug/indication. ² It should be noted that where the BLMK APC is following national guidance, these have been developed with consultation and are required to have been subject to Equality Analysis and Due Regard.</p>
<p>Please state whether the decision will have an impact:</p> <p>Yes <input type="checkbox"/> <i>If YES, the proposal is likely to impact patients or staff. Please set out those impacts and any mitigations that have been identified in the section below. Examples include a process where the needs of exceptional cases can be met.</i></p> <p>No <input type="checkbox"/> <i>NO, please state that the decision has been reviewed with regard to Equality, Inclusion and Human Rights and no issues have been identified in the section below.</i></p>

<p>Provide rationale for impact assessment: <i>Should a significant impact be identified a full EQIA should be completed</i></p>
<p>5) Need for healthcare (incorporates patient choice and exceptional need) <i>e.g. are there alternative therapies available or is this a completely new treatment option?</i></p>
<p>6) Policy drivers: <i>e.g. relevant local or national guidance</i></p>
<p>7) Disinvestment:</p> <ul style="list-style-type: none"> • <i>How will this medicine help to address local health priorities?</i> • <i>By using this medicine, what disinvestment in other medicines, interventions and services may be possible?</i> • <i>How much would this save?</i> • <i>Affordability considerations?</i> • <i>Will this medicine help to address local health priorities?</i>
<p>8) Environmental impact of decision (if applicable)</p>



NICE Technology Appraisal Guidance (CCG/ICB Commissioned) – considered by BLMK APC April 2022 – March 2023

Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea, Technology appraisal guidance [TA777] Published: 09 March 2022 <https://www.nice.org.uk/guidance/ta777> (not recommended)

Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea, Technology appraisal guidance [TA776] Published: 09 March 2022 <https://www.nice.org.uk/guidance/ta776> (not recommended)

Dapagliflozin for treating chronic kidney disease Technology appraisal guidance [TA775] Published: 09 March 2022 <https://www.nice.org.uk/guidance/ta775>

Empagliflozin for treating chronic heart failure with reduced ejection fraction Technology appraisal guidance [TA773] Published: 09 March 2022 <https://www.nice.org.uk/guidance/ta773>

Romosozumab for treating severe osteoporosis Technology appraisal guidance [TA791] Published: 25 May 2022 <https://www.nice.org.uk/guidance/ta791>

Filgotinib for treating moderately to severely active ulcerative colitis Technology appraisal guidance [TA792] Published: 01 June 2022 <https://www.nice.org.uk/guidance/ta792>

Faricimab for treating diabetic macular oedema Technology appraisal guidance [TA799] Published: 29 June 2022 <https://www.nice.org.uk/guidance/ta799>

Faricimab for treating wet age-related macular degeneration Technology appraisal guidance [TA800] Published: 29 June 2022 <https://www.nice.org.uk/guidance/ta800>

Roxadustat for treating symptomatic anaemia in chronic kidney disease Technology appraisal guidance [TA807] Published: 13 July 2022 <https://www.nice.org.uk/guidance/ta807>

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides Technology appraisal guidance [TA805] Published: 13 July 2022 <https://www.nice.org.uk/guidance/ta805>

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs Technology appraisal guidance [TA803] Published: 13 July 2022 <https://www.nice.org.uk/guidance/ta803>

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis Technology appraisal guidance [TA814] Published: 03 August 2022 <https://www.nice.org.uk/guidance/ta814>



Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs Technology appraisal guidance [TA815] Published: 10 August 2022
<https://www.nice.org.uk/guidance/ta815>

Brolucizumab for treating diabetic macular oedema Technology appraisal guidance [TA820] Published: 31 August 2022 <https://www.nice.org.uk/guidance/ta820>

Dexamethasone intravitreal implant for treating diabetic macular oedema Technology appraisal guidance [TA824] Published: 14 September 2022
<https://www.nice.org.uk/guidance/ta824>

Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) Technology appraisal [TA826] Published: 21 September 2022
<https://www.nice.org.uk/guidance/ta826>

Upadacitinib for treating active ankylosing spondylitis Technology appraisal guidance [TA829] Published: 30 September 2022 <https://www.nice.org.uk/guidance/ta829>

Ozanimod for treating moderately to severely active ulcerative colitis Technology appraisal guidance [TA828] Published: 05 October 2022
<https://www.nice.org.uk/guidance/ta828>

Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids Technology appraisal guidance [TA832] Published: 19 October 2022 <https://www.nice.org.uk/guidance/ta832>

Fostamatinib for treating refractory chronic immune thrombocytopenia Technology appraisal guidance [TA835] Published: 19 October 2022
<https://www.nice.org.uk/guidance/ta835>

Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) Technology appraisal [TA838] Published: 02 November 2022 <https://www.nice.org.uk/guidance/ta838>

Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) Technology appraisal [TA844] Published: 24 November 2022
<https://www.nice.org.uk/guidance/ta844>

Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) Technology appraisal [TA847] Published: 29 November 2022
<https://www.nice.org.uk/guidance/ta847>

Esketamine nasal spray for treatment-resistant depression Technology appraisal guidance [TA854] Published: 14 December 2022
<https://www.nice.org.uk/guidance/ta854>

Avatrombopag for treating primary chronic immune thrombocytopenia Technology appraisal guidance [TA853] Published: 15 December 2022
<https://www.nice.org.uk/guidance/ta853>



Upadacitinib for treating moderately to severely active ulcerative colitis Technology appraisal guidance [TA856] Published: 04 January 2023
<https://www.nice.org.uk/guidance/ta856>

Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) Technology appraisal [TA859] Published: 16 January 2023 <https://www.nice.org.uk/guidance/ta859>

Upadacitinib for treating active non-radiographic axial spondyloarthritis Technology appraisal guidance [TA861] Published: 01 February 2023
<https://www.nice.org.uk/guidance/ta861>

Somatrogen for treating growth disturbance in people 3 years and over Technology appraisal guidance [TA863] Published: 01 February 2023
<https://www.nice.org.uk/guidance/ta863>

